Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
November 09, 2015

Top 20 Molecular Millionaires

Biopharma’s Biggest Stakeholders Got Even Richer over the Past Year

Top 20 Molecular Millionaires

Seven executives had stakes in their companies that rose so high in 2014 that they could be called molecular billionaires—compared with just two a year ago. [© Orlando Florin Rosu/Fotolia]

  • For more than a decade, GEN has been tracking what we like to call “molecular millionaires”—CEOs and other executives and relatives with the biggest stakes in biopharma drug development and tools companies.

    With Wall Street and other financial markets still swooning over big biotech well into this year—but not lately—it shouldn’t be too surprising that this year’s list of molecular millionaires saw their stakes balloon over the past year. Seven executives had stakes in their companies that rose so high in 2014 that they could be called molecular billionaires—compared with just two on the GEN List published in 2014.

    The highest-placing executives were those whose companies have launched new products over the past two years—as well as executives of companies that have grown during that period as much through mergers and acquisitions as through any new drugs or tools.

    As in recent years, big pharma maintains only a small presence on this List, with only one executive ranked in the top 20—a retired CEO-turned-chairman (No. 20). Last year’s List saw four big pharma execs, with the highest-ranked person landing at No. 14. The slide reflects the fact the stock of traditional pharma giants did not rise as quickly as that of the biggest biotechs.

    Following is an updated List of 20 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

    Not included on the List are executives from companies that do not derive at least a majority of their revenues from drug development or biopharma tools.

  • #20. Lamberto Andreotti

    Chairman, Bristol-Myers Squibb1

    Total value of all shares:  $190,903,7072

    1,894,409 total shares of common stock and 1,324,335 shares underlying options or stock units as of February 11
     

  • #19. Seamus Mulligan

    Director, Jazz Pharmaceuticals

    Total value of all shares: $207,889,869

    1,167,855 shares of common stock owned as of May 153

  • #18. Jay T. Flatley

    CEO, Illumina

    Total value of all shares: $226,661,428

    1,220,973 total shares of common stock as of March 314

  • #17. Joshua Boger, Ph.D.

    Founder and Director, Vertex Pharmaceuticals5

    Total value of all shares: $254,829,238

    1,983,570 shares of common stock as of April 106

  • #16. Jean-Jacques Bienaimé

    Chairman and CEO, BioMarin Pharmaceutical

    Total value: $268,806,455

    2,147,531 shares of common stock owned as of March 207

  • #15. Leonard Bell, M.D.

    Chairman and principal founder, Alexion Pharmaceuticals; Aditionally served as CEO from the company’s founding in January 1992 until he retired on March 31.

    Total value of all shares: $312,668,757

    1,690,924 shares of common stock as of March 98

  • #14. John F. Milligan

    President and COO, Gilead Sciences

    Total value of all shares: $431,552,485

    4,168,381 shares of common stock as of February 289

  • #13. Robert J. Hugin

    Chairman and CEO, Celgene

    Total value of all shares: $440,726,636

    3,840,755 shares of common stock as of April 2010

Related content